Table A3: Amphetamines
| Prevalence estimates | Entrants into treatment during the year | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| General population | School population | Amphetamines clients as % of treatment entrants | % amphetamines clients injecting (main route of administration) | |||||||
| Year of survey | Lifetime, adults (15–64) | Last 12 months, young adults (15–34) | Lifetime, students (15–16) | All entrants | First-time entrants | Previously treated entrants | All entrants | First-time entrants | Previously treated entrants | |
| Country | % | % | % | % (count) | % (count) | % (count) | % (count) | % (count) | % (count) | |
| Belgium 1 | 2013 | – | 0.5 | 2 | 9.9 (1 160) | 8.6 (345) | 10.7 (794) | 13.5 (130) | 3.9 (11) | 17.8 (118) |
| Bulgaria | 2012 | 1.2 | 1.3 | 6 | 4.7 (84) | 15.9 (51) | 1.6 (16) | 2 (1) | 0 (0) | 0 (0) |
| Czech Republic | 2015 | 4.4 | 2.2 | 1 | 69.7 (7 033) | 75.1 (3 550) | 65 (3 483) | 78.1 (5 446) | 73.8 (2 586) | 82.6 (2 860) |
| Denmark | 2013 | 6.6 | 1.4 | 1 | 6.6 (311) | 6.2 (140) | 7.1 (163) | 4 (11) | 1.7 (2) | 6.2 (9) |
| Germany 3 4 | 2015 | 3.6 | 1.9 | 4 | 16.8 (14 646) | 19.3 (5 134) | 15.7 (9 512) | 2.2 (719) | 1.5 (168) | 2.5 (551) |
| Estonia | 2008 | – | 2.5 | 2 | 2.1 (6) | 3.2 (2) | 2.5 (4) | 66.7 (4) | 100 (2) | 50 (2) |
| Ireland | 2015 | 4.1 | 0.6 | 3 | 0.6 (59) | 0.9 (33) | 0.4 (24) | 3.4 (2) | 3 (1) | 4.2 (1) |
| Greece | – | – | – | 2 | 0.4 (18) | 0.4 (7) | 0.4 (11) | 0 (0) | 0 (0) | 0 (0) |
| Spain | 2015 | 3.6 | 1.0 | 1 | 1.3 (655) | 1.6 (385) | 1.1 (209) | 0.9 (6) | 1.1 (4) | 0.5 (1) |
| France | 2014 | 2.2 | 0.7 | 2 | 0.5 (264) | 0.5 (84) | 0.6 (108) | 11.6 (26) | 14.9 (11) | 15.6 (15) |
| Croatia | 2015 | 3.5 | 2.3 | 3 | 1.4 (102) | 2.7 (23) | 1.1 (74) | – | – | – |
| Italy | 2014 | 2.8 | 0.6 | 2 | 0.2 (91) | 0.3 (59) | 0.1 (32) | 5.2 (4) | 6.4 (3) | 3.3 (1) |
| Cyprus | 2016 | 0.5 | 0.1 | 3 | 4.9 (39) | 3.9 (17) | 5.6 (18) | 2.6 (1) | 5.9 (1) | 0 (0) |
| Latvia | 2015 | 1.9 | 0.7 | 3 | 16.2 (122) | 21.5 (84) | 10.6 (38) | 67.5 (81) | 62.2 (51) | 78.9 (30) |
| Lithuania | 2012 | 1.2 | 0.5 | 1 | 2.5 (63) | 7.1 (28) | 1.5 (31) | 26.7 (16) | 3.7 (1) | 45.2 (14) |
| Luxembourg | – | – | – | – | 0.3 (1) | – | 0.5 (1) | – | – | – |
| Hungary 4 | 2015 | 1.7 | 1.4 | 3 | 11.4 (489) | 12 (354) | 8.9 (98) | 9.6 (46) | 5.7 (20) | 23.7 (23) |
| Malta | 2013 | 0.3 | – | 2 | 0.3 (5) | 0.4 (1) | 0.3 (4) | 20 (1) | – | 25 (1) |
| Netherlands | 2015 | 4.7 | 3.1 | 2 | 7.4 (817) | 7.5 (487) | 7.4 (330) | 1.3 (4) | 1 (2) | 1.9 (2) |
| Austria | 2015 | 2.2 | 0.9 | 3 | 4.8 (174) | 5.7 (75) | 4.2 (99) | 3.8 (6) | 2.9 (2) | 4.3 (4) |
| Poland | 2014 | 1.7 | 0.4 | 4 | 24.3 (2 194) | 25.4 (1 091) | 23.8 (1 056) | 3.7 (80) | 1.7 (18) | 5.8 (60) |
| Portugal | 2012 | 0.5 | 0.1 | 1 | 0.1 (4) | 0.3 (4) | – | 0 (0) | 0 (0) | – |
| Romania | 2013 | 0.3 | 0.1 | 1 | 0.4 (12) | 0.3 (7) | 0.3 (3) | 0 (0) | 0 (0) | 0 (0) |
| Slovenia | 2012 | 0.9 | 0.8 | 1 | 1.3 (4) | 4.5 (4) | 0 (0) | 0 (0) | 0 (0) | – |
| Slovakia | 2015 | 1.4 | 0.8 | 1 | 45.2 (1 132) | 44.7 (539) | 45.4 (559) | 28.7 (315) | 24.3 (129) | 34 (183) |
| Finland | 2014 | 3.4 | 2.4 | 1 | 15.2 (100) | 16.2 (45) | 14.5 (55) | 77.6 (76) | 62.8 (27) | 89.1 (49) |
| Sweden 3 5 6 | 2013 | – | 1.3 | 1 | 7 (2 645) | 8.3 (1 129) | 5.8 (1 376) | – | – | – |
| United Kingdom 2 5 | 2015 | 10.3 | 0.9 | 1 | 2.8 (3 332) | 3.6 (1 414) | 2.4 (1 913) | 18.9 (382) | 11 (89) | 24.3 (293) |
| Turkey | 2011 | 0.1 | 0.1 | – | 1.8 (196) | 2.5 (133) | 1.1 (63) | 0.5 (1) | 0.8 (1) | 0 (0) |
| Norway 3 5 | 2015 | 3.1 | 0.3 | 1 | 13.9 (823) | – | – | – | – | – |
| European Union | – | 3.8 | 1.1 | – | 7.4 (35 562) | 8.4 (15 092) | 7.2 (20 011) | 15.1 (7 357) | 16.8 (3 128) | 14.1 (4 217) |
| EU, Turkey and Norway | – | – | – | – | 7.3 (36 581) | 8.2 (15 225) | 7.1 (20 074) | 15 (7 358) | 16.6 (3 129) | 14.1 (4 217) |
NB
Prevalence estimates for the school population are taken from national school surveys or the ESPAD project. Due to uncertainty of data collection procedures, Latvia data may not be comparable.
- Prevalence estimates for the general population refer to Flanders only. ↩
- Prevalence estimates for the general population refer to England and Wales only. ↩
- Age range for prevalence estimates in the general population: 18–64, 18–34. ↩
- Age range for prevalence estimates in the general population: 16–64, 16–34. ↩
- First-time and previously treated entrants are available only for two of the three data sources available in Sweden and, therefore, not comparable with data for all entrants. ↩